BioCryst Q2 ORLADEYO revenue up 34% to $108.3M; raises FY guidance to $420-435M

BIOCRYST PHARMACEUTICALS INC

2024-Q2 EPS reported -$0.23 revenue$202,093,000

Q2 total revenue $109.3M (+32.5% YoY); GAAP operating profit $8.8M vs loss $20.7M in Q2 2023.
Net loss narrowed to $12.7M ($0.06/share) from $75.3M ($0.40/share); non-GAAP operating profit $21.9M.
ORLADEYO FY2024 revenue guidance raised to $420-435M from $390-400M, citing strong demand and payer improvements.
Discontinuing oral Factor D inhibitor BCX10013 due to insufficient activity; advancing BCX17725 for Netherton syndrome to clinic by end-2024.
Cash $338.1M vs $415.7M a year ago; operating cash use was only $0.2M in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.